Pfizer's PGx NSCLC Drug Yields Promising PFS Results; More Research Needed to Map Disease Mechanism

"The median progression-free survival [with crizotinib] far exceeds anything that one would expect with standard therapy in this heavily pretreated group," Nasser Hanna of Indiana University said in a presentation at ASCO reviewing interim Phase I data on the drug.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.